We hypothesised that the 100 μg dose might increase plasma adiponectin concentration (indicative of a reduced risk of type-2 diabetes) by optimising selenoprotein activity, whereas the much higher 300 μg dose might potentially have an adverse effect. Here, ADIPOQ is linked to type 2 diabetes mellitus.